Lupin clinches FDA approval for generic Spiriva HandiHaler

Pallavi Madhiraju- June 21, 2023

Indian pharma titan Lupin has announced receiving approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Tiotropium Bromide ... Read More

Lupin ropes in Spiro Gavaris as US generics business president

Pallavi Madhiraju- December 11, 2022

Indian pharmaceutical company Lupin Limited has appointed Spiro Gavaris as president of its US generics business. Spiro Gavaris, who will be a part of the ... Read More

Lupin to acquire rights to Brovana and Xopenex HFA for $75m

Pallavi Madhiraju- October 20, 2022

Lupin Limited has agreed to acquire all rights to a couple of inhalation medicines, namely Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) ... Read More

Shahin Fesharaki appointed as Lupin Global Chief Scientific Officer

Pallavi Madhiraju- October 10, 2022

Indian pharmaceutical company Lupin announced that Dr. Shahin Fesharaki has been appointed as Global Chief Scientific Officer who will handle global research and development works ... Read More

Lupin Pharmaceuticals signs agreement with Exeltis to promote Solosec in US

pallavi123- January 27, 2022

Indian pharma company Lupin Pharmaceuticals has signed an agreement with Exeltis USA to promote its antimicrobial drug Solosec (secnidazole) in the US market. Solosec is ... Read More

Lupin gets EIR with voluntary action indicated from FDA for Goa facility

pallavi123- December 14, 2021

Lupin Limited said that it has been issued the establishment inspection report (EIR) from the US Food and Drug Administration (US FDA) for its manufacturing ... Read More

Lupin Limited gets approval for Luforbec 100/6 µg pMDI in UK

pallavi123- June 20, 2021

Lupin Limited said that its subsidiary Lupin Healthcare (UK) has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Luforbec (beclometasone dipropionate/formoterol ... Read More